STOCK TITAN

Incyte president Pablo J. Cagnoni sells 2,642 shares

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
4

Rhea-AI Filing Summary

Pablo J. Cagnoni, Incyte Corporation’s President, Global Head of R&D, exercised options for 2,642 shares on November 16, 2026, at exercise prices of $61.18, $61.76, $64.25 and $71.93 per share. He also sold 2,642 shares: 877 at $121.98 and 1,765 at $120.46 per share. The transactions were reported under a Rule 10b5-1 plan.

Insider CAGNONI PABLO J
Role President, Global Head of R&D
Sold 2,642 shs ($320K)
Approx. gross sale proceeds $320K
Approx. exercise cost $174K
Approx. pre-tax spread $146K
Share of Position Sold 1.4%
Type Security Shares Price Value
Exercise Employee Stock Option (right to buy) F2 455 $0.00 $0.00
Exercise Employee Stock Option (right to buy) F3 422 $0.00 $0.00
Exercise Employee Stock Option (right to buy) F4 926 $0.00 $0.00
Exercise Employee Stock Option (right to buy) F5 839 $0.00 $0.00
Exercise Common Stock 455 $61.18 $28K
Exercise Common Stock 422 $61.76 $26K
Exercise Common Stock 926 $64.25 $59K
Exercise Common Stock 839 $71.93 $60K
Sale Common Stock 877 $121.98 $107K
Sale Common Stock F1 1,765 $120.46 $213K
Holdings After Transaction: Employee Stock Option (right to buy) — 42,314 options (Direct); Common Stock — 183,200 shares (Direct)
Holdings Before and After: Employee Stock Option (right to buy), 44,956 to 42,314 options (Direct); Common Stock, 183,200 to 183,200 shares (Direct)
Other Insiders: 3 other insiders reported open-market sales of this stock in the 30 days up to this filing.
Footnotes (5)
  1. F1. This includes an aggregate of 183,200 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested.
  2. F2. Beginning January 18, 2024, options become exercisable in 37 installments, with the first 25% vesting on July 14, 2024 and the remainder vesting monthly over three years.
  3. F3. The July 14, 2023 options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years.
  4. F4. The July 15, 2024 options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years.
  5. F5. Beginning January 17, 2025, options become exercisable in 37 installments, with the first 25% vesting on July 15, 2025 and the remainder vesting monthly over three years.
Options exercised 2,642 shares November 16, 2026; four option lots
Option exercise prices $61.18, $61.76, $64.25 and $71.93 per share For option lots of 455, 422, 926 and 839 shares, respectively
Shares sold 877 shares November 16, 2026, at $121.98 per share
Sale price $121.98 per share For the sale of 877 shares on November 16, 2026
Shares sold 1,765 shares November 16, 2026, at $120.46 per share
Sale price $120.46 per share For the sale of 1,765 shares on November 16, 2026
Employee Stock Option (right to buy) financial
"the Employee Stock Option (right to buy) reported for November 16, 2026"
restricted stock units financial
"shares issuable pursuant to previously reported restricted stock units"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
earned performance stock units financial
"earned performance stock units that have not vested"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many shares did INCY executive Pablo J. Cagnoni sell?

Pablo J. Cagnoni sold 2,642 shares in two transactions on November 16, 2026: 877 shares at $121.98 per share and 1,765 shares at $120.46 per share. The transactions were reported under a Rule 10b5-1 plan.

What options did INCY executive Pablo J. Cagnoni exercise?

He exercised options for 2,642 shares at prices of $61.18, $61.76, $64.25 and $71.93 per share on November 16, 2026.

When do the exercised INCY options expire?

The reported option lots expire on January 17, 2034; July 13, 2033; July 14, 2034; and January 16, 2035. These dates correspond, respectively, to the lots of 455, 422, 926 and 839 shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
CAGNONI PABLO J

(Last)(First)(Middle)
1801 AUGUSTINE CUT-OFF

(Street)
WILMINGTON DELAWARE 19803

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
INCYTE CORP [ INCY ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
President, Global Head of R&D
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
11/16/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock11/16/2026M455A$61.18183,655D
Common Stock11/16/2026M422A$61.76184,077D
Common Stock11/16/2026M926A$64.25185,003D
Common Stock11/16/2026M839A$71.93185,842D
Common Stock11/16/2026S877D$121.98184,965D
Common Stock11/16/2026S1,765D$120.46183,200(1)D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Employee Stock Option (right to buy)$61.1811/16/2026M455 (2)01/17/2034Common Stock455$03,641D
Employee Stock Option (right to buy)$61.7611/16/2026M422 (3)07/13/2033Common Stock422$03,380D
Employee Stock Option (right to buy)$64.2511/16/2026M926 (4)07/14/2034Common Stock926$018,505D
Employee Stock Option (right to buy)$71.9311/16/2026M839 (5)01/16/2035Common Stock839$016,788D
Explanation of Responses:
1. This includes an aggregate of 183,200 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested.
2. Beginning January 18, 2024, options become exercisable in 37 installments, with the first 25% vesting on July 14, 2024 and the remainder vesting monthly over three years.
3. The July 14, 2023 options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years.
4. The July 15, 2024 options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years.
5. Beginning January 17, 2025, options become exercisable in 37 installments, with the first 25% vesting on July 15, 2025 and the remainder vesting monthly over three years.
Remarks:
/s/ Elizabeth Feeney, Attorney-In-Fact11/18/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Keep reading